 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...51525354555657585960616263» |
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Phase 4 Study of Dolutegravir (DTG) in Russian Federation (clinicaltrials.gov) - Oct 19, 2017
P4, N=34, Recruiting, Sponsor: ViiV Healthcare
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Enrollment change, Trial initiation date, Trial primary completion date, Monotherapy, Head-to-Head: Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection (clinicaltrials.gov) - Oct 10, 2017
P2, N=101, Active, not recruiting, Sponsor: University of Zurich
Recruiting --> Active, not recruiting | N=138 --> 101 | Initiation date: Nov 2015 --> Nov 2016 | Trial primary completion date: Mar 2017 --> Feb 2018
- Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir (clinicaltrials.gov) - Oct 9, 2017
P=N/A, N=20, Active, not recruiting, Sponsor: Southern Illinois Healthcare Foundation
Recruiting --> Active, not recruiting | N=138 --> 101 | Initiation date: Nov 2015 --> Nov 2016 | Trial primary completion date: Mar 2017 --> Feb 2018 Trial primary completion date: Jul 2017 --> Dec 2017
- | Enrollment closed: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Oct 6, 2017
P3, N=224, Active, not recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Jul 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Sep 27, 2017
P=N/A, N=403, Active, not recruiting, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | GSK3532795 / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Trial termination, Trial primary completion date, Combination therapy: Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults (clinicaltrials.gov) - Sep 26, 2017
P2b, N=84, Terminated, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jun 2017; GI Intolerability
- ||||||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Trial primary completion date: ASPIRE: Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (clinicaltrials.gov) - Sep 13, 2017
P3, N=90, Completed, Sponsor: Babafemi Taiwo
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jun 2017; GI Intolerability Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2017
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir (clinicaltrials.gov) - Sep 7, 2017
P1, N=38, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2017 Not yet recruiting --> Completed
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: D (clinicaltrials.gov) - Aug 31, 2017
P3b/4, N=610, Not yet recruiting, Sponsor: Kirby Institute
Not yet recruiting --> Completed Initiation date: Jul 2017 --> Sep 2017
- | Selzentry (maraviroc) / ViiV Healthcare
Trial primary completion date, Combination therapy: Switch to Maraviroc + Integrase Inhibitor (clinicaltrials.gov) - Aug 22, 2017
P3, N=30, Recruiting, Sponsor: University of Maryland
Initiation date: Jul 2017 --> Sep 2017 Trial primary completion date: Jul 2017 --> Dec 2017
- |||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, IO biomarker: A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir (clinicaltrials.gov) - Aug 22, 2017
P2, N=110, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Jul 2017 --> Dec 2017 Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: DolPHIN-2: Dolutegravir in Pregnant HIV Mothers and Their Neonates (clinicaltrials.gov) - Aug 14, 2017
P3, N=250, Not yet recruiting, Sponsor: University of Liverpool
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial primary completion date: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Aug 9, 2017
P=N/A, N=400, Recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Trial primary completion date: Jul 2018 --> Oct 2018
- | Trial primary completion date: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Aug 2, 2017
P2, N=84, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jul 2018 --> Oct 2018 Trial primary completion date: Jan 2019 --> Jul 2018
- | Tivicay (dolutegravir) / ViiV Healthcare
New P2 trial: Dolutegravir Plus 2 NRTIs, in Treatment-Na (clinicaltrials.gov) - Jul 21, 2017
P2, N=30, Recruiting, Sponsor: Blueclinical, Ltd.
- ||||| Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date, Head-to-Head, IO biomarker: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment na (clinicaltrials.gov) - Jul 19, 2017
P3, N=700, Active, not recruiting, Sponsor: ViiV Healthcare
Trial primary completion date: Jan 2019 --> Jul 2018 Initiation date: Jan 2016 --> Jul 2016
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed, Trial primary completion date: Lighthouse: Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). (clinicaltrials.gov) - Jul 18, 2017
P2a, N=40, Active, not recruiting, Sponsor: Neuroscience Trials Australia
Initiation date: Jan 2016 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2017
- | Selzentry (maraviroc) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial, Adherence: ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence (clinicaltrials.gov) - Jul 13, 2017
P4, N=36, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change: Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers (clinicaltrials.gov) - Jul 11, 2017
P1, N=30, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2017 N=60 --> 30
- ||||| Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date, Head-to-Head, IO biomarker: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment na (clinicaltrials.gov) - Jul 7, 2017
P3, N=700, Active, not recruiting, Sponsor: ViiV Healthcare
N=60 --> 30 Initiation date: Jul 2016 --> Jan 2016
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: Dualis: Dual Therapy With Boosted Darunavir + Dolutegravir (clinicaltrials.gov) - Jul 6, 2017
P3, N=320, Recruiting, Sponsor: Technische Universit
Initiation date: Jul 2016 --> Jan 2016 Trial primary completion date: Mar 2018 --> Jun 2018
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers (clinicaltrials.gov) - Jul 5, 2017
P1, N=60, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Mar 2018 --> Jun 2018 Suspended --> Recruiting
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Enrollment open: POPARV: Population Pharmacokinetics of Antiretroviral in Children (clinicaltrials.gov) - Jul 4, 2017
P=N/A, N=700, Recruiting, Sponsor: Assistance Publique - H
Suspended --> Recruiting Not yet recruiting --> Recruiting
- |||| Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial completion, IO biomarker: Renal Integrase Study (clinicaltrials.gov) - Jun 27, 2017
P4, N=60, Completed, Sponsor: St Stephens Aids Trust
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: RADIO: A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers (clinicaltrials.gov) - Jun 26, 2017
P1, N=16, Not yet recruiting, Sponsor: St. Stephens Clinical Research
- Tivicay (dolutegravir) / ViiV Healthcare
New trial: A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=20, Active, not recruiting, Sponsor: Southern Illinois Healthcare Foundation
- |||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed (clinicaltrials.gov) - Jun 26, 2017
P3, N=520, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
New trial: POPARV: Population Pharmacokinetics of Antiretroviral in Children (clinicaltrials.gov) - Jun 20, 2017
P=N/A, N=700, Not yet recruiting, Sponsor: Assistance Publique - H
- ||||||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Combination therapy: FLAMINGO: Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (clinicaltrials.gov) - Jun 20, 2017
P3, N=488, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) - Jun 14, 2017
P4, N=44, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| GSK3532795 / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date, Combination therapy: Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults (clinicaltrials.gov) - May 31, 2017
P2b, N=84, Active, not recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Initiation date: Feb 2015 --> Jul 2015
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: SSAT073: The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers (clinicaltrials.gov) - Apr 30, 2017
P1, N=20, Recruiting, Sponsor: St Stephens Aids Trust
Initiation date: Feb 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- | Trial primary completion date: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Apr 26, 2017
P2, N=84, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Jan 2019
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P3 trial, Head-to-Head: ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (clinicaltrials.gov) - Apr 20, 2017
P3, N=1110, Recruiting, Sponsor: Willem Daniel Francois Venter
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change: Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers (clinicaltrials.gov) - Apr 18, 2017
P1, N=4, Suspended, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Apr 2017 --> Jan 2019 N=60 --> 4
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: D (clinicaltrials.gov) - Apr 13, 2017
P3b/4, N=610, Not yet recruiting, Sponsor: Kirby Institute
N=60 --> 4 Initiation date: Apr 2017 --> Jul 2017
- ||||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Head-to-Head, IO biomarker: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment na (clinicaltrials.gov) - Apr 12, 2017
P3, N=700, Active, not recruiting, Sponsor: ViiV Healthcare
Initiation date: Apr 2017 --> Jul 2017 Recruiting --> Active, not recruiting
- |||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed (clinicaltrials.gov) - Apr 12, 2017
P3, N=520, Not yet recruiting, Sponsor: Gilead Sciences
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: SSAT073: The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers (clinicaltrials.gov) - Mar 29, 2017
P1, N=20, Not yet recruiting, Sponsor: St Stephens Aids Trust
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir (clinicaltrials.gov) - Mar 29, 2017
P1, N=38, Not yet recruiting, Sponsor: ViiV Healthcare
- |||||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial initiation date, Trial primary completion date: DolPHIN1: Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study (clinicaltrials.gov) - Mar 15, 2017
P2/3, N=60, Recruiting, Sponsor: University of Liverpool
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Mar 2017 | Trial primary completion date: Sep 2016 --> Sep 2017
- ||| GSK3532795 / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Enrollment change, Trial initiation date, Combination therapy: Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults (clinicaltrials.gov) - Mar 8, 2017
P2b, N=84, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Mar 2017 | Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting | N=200 --> 84 | Initiation date: Jun 2015 --> Feb 2015
- |||| Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date, Head-to-Head, IO biomarker: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment na (clinicaltrials.gov) - Feb 17, 2017
P3, N=700, Recruiting, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting | N=200 --> 84 | Initiation date: Jun 2015 --> Feb 2015 Trial primary completion date: Dec 2017 --> Apr 2018
- Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date, Adherence: DOLUTECAPS: Adherence to Dolutegravir and Outcome (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=120, Recruiting, Sponsor: University Hospital, Caen
Trial primary completion date: Dec 2017 --> Apr 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- ||||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change: AAHIV: Antiretroviral Therapy for Acute and Chronic HIV Infection (clinicaltrials.gov) - Jan 30, 2017
P3, N=500, Recruiting, Sponsor: South East Asia Research Collaboration with Hawaii
Trial primary completion date: Dec 2016 --> Dec 2017 N=150 --> 500
- Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: DOLBI: Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=100, Recruiting, Sponsor: Asociacion para el Estudio de las Enfermedades Infecciosas
N=150 --> 500 Trial primary completion date: Dec 2016 --> Mar 2017
- Selzentry (maraviroc) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=30, Active, not recruiting, Sponsor: Federal University of S
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- ||||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Trial primary completion date: ASPIRE: Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (clinicaltrials.gov) - Jan 19, 2017
P3, N=90, Active, not recruiting, Sponsor: Babafemi Taiwo
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2017
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Trial primary completion date: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jan 10, 2017
P1, N=20, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Trial primary completion date: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Jan 4, 2017
P3, N=250, Recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Aug 2017